Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Harmonized Clinical Trial Methodologies for Localized Cutaneous Leishmaniasis and Potential for Extensive Network With Capacities for Clinical Evaluation Publisher Pubmed



Olliaro P1, 2 ; Grogl M3 ; Boni M4 ; Carvalho EM5 ; Chebli H6 ; Cisse M7 ; Diro E8 ; Fernandes Cota G9 ; Erber AC10 ; Gadisa E11 ; Handjani F12 ; Khamesipour A13 ; Llanoscuentas A14 ; Lopez Carvajal L15 Show All Authors
Authors
  1. Olliaro P1, 2
  2. Grogl M3
  3. Boni M4
  4. Carvalho EM5
  5. Chebli H6
  6. Cisse M7
  7. Diro E8
  8. Fernandes Cota G9
  9. Erber AC10
  10. Gadisa E11
  11. Handjani F12
  12. Khamesipour A13
  13. Llanoscuentas A14
  14. Lopez Carvajal L15
  15. Grout L16
  16. Lmimouni BE17
  17. Mokni M18
  18. Nahzat MS19
  19. Ben Salah A20
  20. Ozbel Y21
  21. Pascale JM22
  22. Rizzo Molina N23
  23. Rode J4
  24. Romero G24
  25. Ruizpostigo JA16
  26. Gore Saravia N25
  27. Soto J26
  28. Uzun S27
  29. Mashayekhi V28
  30. Velez ID15
  31. Vogt F29
  32. Zerpa O30
  33. Arana B31

Source: PLoS Neglected Tropical Diseases Published:2018


Abstract

Introduction: Progress with the treatment of cutaneous leishmaniasis (CL) has been hampered by inconsistent methodologies used to assess treatment effects. A sizable number of trials conducted over the years has generated only weak evidence backing current treatment recommendations, as shown by systematic reviews on old-world and new-world CL (OWCL and NWCL). Materials and methods: Using a previously published guidance paper on CL treatment trial methodology as the reference, consensus was sought on key parameters including core eligibility and outcome measures, among OWCL (7 countries, 10 trial sites) and NWCL (7 countries, 11 trial sites) during two separate meetings. Results: Findings and level of consensus within and between OWCL and NWCL sites are presented and discussed. In addition, CL trial site characteristics and capacities are summarized. Conclusions: The consensus reached allows standardization of future clinical research across OWCL and NWCL sites. We encourage CL researchers to adopt and adapt as required the proposed parameters and outcomes in their future trials and provide feedback on their experience. The expertise afforded between the two sets of clinical sites provides the basis for a powerful consortium with potential for extensive, standardized assessment of interventions for CL and faster approval of candidate treatments. © 2018 Public Library of Science. All Rights Reserved.
Other Related Docs
8. Epidemiological Aspects of Cutaneous Leishmaniasis in Iran, Archives of Clinical Infectious Diseases (2015)
9. Vaccines for Preventing Cutaneous Leishmaniasis, Cochrane Database of Systematic Reviews (2018)
15. Situation Analysis of Cutaneous Leishmaniasis in an Endemic Area, South of Iran, Asian Pacific Journal of Tropical Medicine (2017)
18. Delivery Systems for Leishmania Vaccine Development, Expert Review of Vaccines (2016)